Por labores de mantenimiento, el Repositorio Institucional UCAM (RIUCAM) dejará de estar disponible a partir del martes 13 de octubre y hasta nuevo aviso. Disculpen las molestias.

Mostrar el registro sencillo del ítem

dc.contributor.authorAndrade Alarcón, Deric
dc.contributor.authorde la Asunción Nadal, Víctor
dc.contributor.authorCrespo, Gastón A.
dc.contributor.authorCuartero, María
dc.date.accessioned2026-10-05T09:36:08Z
dc.date.available2026-10-05T09:36:08Z
dc.date.issued2025-10-30
dc.identifier.citationAndrade‐Alarcón, D., De La Asunción‐Nadal, V., Crespo, G. A., & Cuartero, M. (2026). Tailored core‐shell nanocarrier for therapeutic drug delivery via visible light activation. Angewandte Chemie, 138(2), e202514317. https://doi.org/10.1002/ange.202514317es
dc.identifier.urihttp://hdl.handle.net/10952/11231
dc.description.abstractWe present a novel drug delivery nanocarrier consisting of 300 nm-sized POT/Fe3 O 4 /TRZ+TPB− nanoparticles(NPs). The mechanism is based on the (photo)oxidation of poly(3-octylthiophene-2,5-diyl) (POT) (from POT 0 to POT+),which facilitates the release of the positively charged drug trazodone (TRZ+) encapsulated in the NPs. The primaryfactor guiding the overall process is the maintenance of the electroneutrality condition in each NP. The incorporationof a Fe 3 O 4 element enables the formation of an organic-inorganic heterojunction (Fe3 O 4 /POT) in the core of the NP. Thisheterojunction permits us to utilize visible light to induce the POT photooxidation to trigger the release of TRZ+, unlikeother platforms based on a more energetic illumination requirement. The developed nanocarrier allows for a controlleddrug release, achieving doses of 3.5 µg mL−1 of TRZ under 530 nm irradiation, 2.4 µg mL−1 at 625 nm, and 1.6 µg mL−1at 470 nm within 1 h. The delivery is tested in undiluted blood serum, achieving an efficiency exceeding 90%. Overall,the integration of magnetic properties with a conductive polymer along with the adjustment of the band gap to enhancephotooxidation performance in the visible range, constitute the conceptual innovation behind the controlled drug deliverysystem here presented, with TRZ as a model.es
dc.language.isoenes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectConductive polymerses
dc.subjectDrug encapsulationes
dc.subjectHeterojunctiones
dc.subjectIon-selective membraneses
dc.subjectNanoparticleses
dc.titleTailored Core-Shell Nanocarrier for Therapeutic Drug Delivery via Visible Light Activationes
dc.typejournal articlees
dc.rights.accessRightsopen accesses
dc.journal.titleAngewandte Chemiees
dc.volume.number138es
dc.issue.number2es
dc.description.disciplineFarmaciaes
dc.identifier.doi10.1002/ange.202514317es
dc.description.facultyUCAMSENSes
dc.type.hasVersionVoRes


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional